^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
Breast Cancer Index®

Company:
Hologic
Type:
Laboratory Developed Test
Related tests:
Evidence

News

16d
Lifestyle Factors and Breast Cancer in Females with PTEN Hamartoma Tumor Syndrome (PHTS). (PubMed, Cancers (Basel))
Similar associations between lifestyle and breast cancer are suggested for PHTS and the general population. Despite not being statistically significant, results are clinically relevant and suggest that awareness of the effects of lifestyle on patients' breast cancer risk is important.
Journal
|
PTEN (Phosphatase and tensin homolog)
|
Breast Cancer Index®
24d
Impact of the Breast Cancer Index for Extended Endocrine Decision-Making: First Results of the Prospective BCI Registry Study. (PubMed, J Natl Compr Canc Netw)
This analysis in a large patient cohort of the BCI Registry confirms and extends previous findings on the significant decision-making impact of BCI on EET. Incorporating BCI into clinical practice resulted in changes in physician recommendations, increased physician confidence, improved patient satisfaction, and reduced patient concerns regarding the cost, drug safety, and benefit of EET.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive
|
Breast Cancer Index®
|
tamoxifen
24d
Newly Published Results Reveal a Significant Proportion of Early-Stage HR+ Breast Cancer Survivors May Be Over- or Undertreated Without Breast Cancer Index Genomic Testing (Businesswire)
"Hologic, Inc...today announced newly published study results revealing that use of the Breast Cancer Index (BCI) test led to physicians changing their long-term anti-estrogen treatment recommendations for 40% of patients with early-stage hormone receptor-positive (HR+) breast cancer. The results, which suggest that many women may be over- or undertreated without the incorporation of BCI, reflect real-world data from the largest prospective study assessing the impact of the BCI test on treatment decisions...Patients and physicians included in this study are participants in the BCI Registry Study....newly published findings reveal that when incorporated into routine clinical care, BCI has the potential to provide clinicians with greater confidence in their treatment recommendations, with 39% of providers saying they felt more confident in their recommendation for extended anti-estrogen therapy following BCI testing."
Real-world evidence
|
Breast Cancer Index®
1m
Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial. (PubMed)
BCI(H/I)-High vs -Low did not show a statistically significant difference in ELT benefit for the primary endpoint (RFI). However, in time-dependent DR analysis, BCI (H/I)-High patients experienced statistically significant benefit from ELT after 4y, whereas (H/I)-Low patients did not. Because BCI (H/I) has been validated as a predictive marker of EET benefit in other trials, additional follow-up may enable further characterization of BCI's predictive ability.
Journal
|
Breast Cancer Index®
|
letrozole
2ms
Validation of the prognostic performance of Breast Cancer Index (BCI) in hormone receptor-positive (HR+) postmenopausal breast cancer patients in the TEAM trial. (PubMed, Clin Cancer Res)
The TEAM trial represents the largest prognostic validation study for BCI to date and provides a more representative assessment of late DR risk to guide individualized treatment decision-making for HR+ early-stage breast cancer patients.
Journal
|
HR positive
|
Breast Cancer Index®
2ms
Enrollment closed
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HR positive • HER-2 negative • PGR positive
|
Breast Cancer Index®
5ms
Breast Cancer Index (BCI) results from a HER2 low breast cancer community cohort of operable stage I-II hormone receptor positive (HR+) breast cancer (SABCS 2023)
Of the 32 HER2-low tumors, 15/32 (47%) were BCI (H/I)-High (yes benefit) compared to 17/32 (53%) which were BCI (H/I)-Low (no benefit). Conclusions The prevalence of HER2 low tumors appears to be as high as 67% in reports to date. In this small series, the prevalence of HR+ HER2 low tumors was 29% (32/110).
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative
|
Breast Cancer Index®
5ms
Breast Cancer Index and comparative analysis of late distant recurrence risk with results from the TEAM trial (SABCS 2023)
The current BCI assay reports prognostic risk estimates based on tamoxifen-treated patients from the Stockholm (STO-3) cohort for node-negative (N0) patients, enrolled between 1976 through 1990 and a retrospective cohort from Massachusetts General Hospital (MGH) for patients with 1 to 3 positive nodes (N1), diagnosed between 1993 and 2007, of which approximately 50% were tamoxifen-treated... BCI prognostic validation in the TEAM trial enabled the characterization of DR risk that is more compatible with the current standard of care in the US, as postmenopausal patients were all treated with at least 2-3 years or 5 years of primary adjuvant endocrine therapy with an aromatase inhibitor. Results from the TEAM study provide a more representative assessment of late DR risk to guide individualized treatment decision-making for HR+ early-stage breast cancer patients.
Breast Cancer Index®
|
tamoxifen
5ms
Differential HOXB13 gene expression and promoter methylation analysis in breast cancer (SABCS 2023)
A comprehensive and comparative analysis of mRNA expression levels and methylation patterns between TCGA breast cancer samples with high and low expression of HOXB13 revealed key signaling pathways and biological processes that may provide insights on the molecular mechanism of HOXB13 in the regulation of response to endocrine therapy in HR+ breast cancer.
ER (Estrogen receptor) • CDK4 (Cyclin-dependent kinase 4) • FOXA1 (Forkhead Box A1) • FOXP1 (Forkhead Box P1) • IL17A (Interleukin 17A) • HOXB13 (Homeobox B13) • IL17RB (Interleukin 17 Receptor B) • PTK6 (Protein Tyrosine Kinase 6)
|
HR positive • HOXB13 expression
|
Breast Cancer Index®
5ms
Correlative analysis of Breast Cancer Index with CTS5 for prediction of extended endocrine benefit in the BCI Registry study (SABCS 2023)
Conclusion BCI (H/I) consistently stratified CTS5 risk categories into separate BCI (H/I)-Low and BCI (H/I)-High groups, indicating that risk prognostication does not equate to prediction of benefit from EET. These results confirm previous findings in the IDEAL study demonstrating that CTS5 is not predictive of EET benefit and further substantiate the clinical utility of BCI as the only predictive biomarker for extended endocrine therapy benefit in patients with HR+ early-stage breast cancer.
HOXB13 (Homeobox B13) • IL17RB (Interleukin 17 Receptor B)
|
HR positive
|
Breast Cancer Index®
5ms
Chinese expert consensus on multigene testing for adjuvant treatment of HR-positive, HER-2 negative early breast cancer(2023 edition) (PubMed, Zhonghua Zhong Liu Za Zhi)
The development and validation process of each tool was also briefly introduced. It is expected that the consensus will help guide and standardize the clinical use of multigene testing tools and further improve the level of precise treatment for EBC.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative
|
MammaPrint • Breast Cancer Index® • EndoPredict® • Oncotype DX Breast Recurrence Score®Test • RecurIndex®
5ms
Biomarkers predictive of a response to extended endocrine therapy in breast cancer: a systematic review and meta-analysis. (PubMed, Breast Cancer Res Treat)
Evidence in the setting of predictive tests for extended endocrine therapy is sparse. Most relevant studies investigated the use of BCI, but these study populations were largely restricted to a single age, race, and ethnicity group. Future studies should evaluate a variety of biomarkers in diverse populations. Without sufficient evidence, physicians and patients face a difficult decision in balancing the benefits and risks of endocrine therapy extension.
Journal • Retrospective data • Review
|
Breast Cancer Index®
6ms
Clinical presentations and prognostication of HER2-low breast cancer in Taiwan (ESMO Asia 2023)
Conclusions HER2-low status is not a prognostic marker for Taiwanese breast cancers while a slightly younger age of disease onset, less than half diagnosed with stage 0 and I, more ER and PR positivity and fewer grade III disease were observed for HER2-low phenotype compared with HER2-zero counterpart. These trivial differences distinguished HER2-low from HER2-zero spectrum among Taiwanese HER2-negative breast cancers.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative
|
Breast Cancer Index®
7ms
Precision medicine in extended adjuvant endocrine therapy for breast cancer. (PubMed, Curr Opin Oncol)
Even after 5 years of adjuvant endocrine therapy, patients with hormone receptor-positive breast cancer have a significant risk for late recurrence, including distant metastases, that might be prevented with longer durations of endocrine therapy. However, the added toxicity and variable benefit derived from extended endocrine therapy make optimal patient selection crucial. Genomic assays are in development to risk-stratify patients for late recurrence and determine efficacy of extended endocrine therapy, with the aim to help guide extended endocrine therapy decisions for clinicians and individualize treatment strategies for patients.
Journal
|
HR positive
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • Breast Cancer Index® • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
9ms
Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer. (PubMed, BMC Cancer)
In patients who continued ET after BCI testing, the rates of persistence to EET were high, particularly in patients with predicted high likelihood of benefit from EET. Use of EET is associated with increased use of DXA scans.
Journal
|
HR positive
|
Breast Cancer Index®
10ms
No more disparities among regions in Italy: recent approval of genomic test reimbursability for early breast cancer patients in the country. (PubMed, Breast Cancer Res Treat)
The establishment of criteria used to perform molecular tests in BC patients needs to be standardized, and the tests should be performed in specialized laboratories. Test centralization and reimbursement are fundamental to be able to compare the outcome of patients treated or not with chemotherapy in addition to hormone therapy to verify data from clinical randomized studies in a real-world setting.
Journal
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint • Breast Cancer Index® • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
11ms
Assessment of risk of overall and late distant recurrence by Breast Cancer Index in postmenopausal women with early-stage, HR+ breast cancer in the TEAM trial. (ASCO 2023)
Previously, we have shown that the Breast Cancer Index (BCI) and BCIN+ risk groups are significantly prognostic for risk of overall (0-10y) and late (5-10y) distant recurrence in N0 and N1 breast cancer patients, respectively, enrolled in the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial. Results from this largest BCI study to date further support the use of BCI to provide individualized risk estimates for both overall and late DR in women with HR+ breast cancer to aid in personalized decision-making for adjuvant therapy. >
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
Breast Cancer Index®
|
tamoxifen • exemestane
11ms
An analysis of breast cancer index scores predicting benefit of extended endocrine therapy by race. (ASCO 2023)
Our findings highlight the utility of characterizing differences in BCI predictive and prognostic scores by race among breast cancer patients with early-stage HR+ tumors. Notably, Native Hawaiian women had 7.0 times increased odds of having a score predicting benefit of extended endocrine therapy compared to Caucasians. This result is salient given the high incidence of breast cancer among Native Hawaiians.
HR positive
|
Breast Cancer Index®
11ms
Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, Influence, CTS-5)? A TEAM Pathology substudy. (ASCO 2023)
The TEAM pathology study consists of 3284 postmenopausal hormone positive breast cancer patients treated with either exemestane or tamoxifen followed by exemestane. Other clinico-pathologic tools such as Influence 2.0 and CTS-5 have good prognostic ability when compared to Oncotype Dx-trained results and RSClin. >
MammaPrint • Breast Cancer Index® • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
|
tamoxifen • exemestane
1year
The lack of documentation of patient's body mass index (BMI) in recent clinical trials (ESMO-BC 2023)
Conclusions This study emphasizes that most drugs are given at fixed dose and the gap in knowledge we have on the efficacy of the novel anti-cancer treatments and the use of GEP and MS according to patient adiposity. As the prevalence of obesity is increasing worldwide, the evaluation of body composition is needed to increase knowledge on optimal use of drugs in clinical practice.
Clinical • PARP Biomarker • IO biomarker
|
ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint • Breast Cancer Index® • EndoPredict® • OncoMasTR test • Oncotype DX Breast Recurrence Score®Test
1year
Duration of endocrine therapy in early breast cancer (SG-BCC 2023)
However most of this data was generated with tamoxifen monotherapy during the first 5 years...This must be balanced against long term side effects of endocrine treatment, competing risks like the patients (biological) age and comorbidities and obviously the patients preferrence. For patients with intermediate risk 7 years appears to be the optimal duration and in those with high risk features endocrine therapy up to 10 years may be considered.
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
|
Breast Cancer Index®
|
tamoxifen
1year
Predicting Response to CDK4/6 Inhibitors in Breast Cancer (USCAP 2023)
Design: In this cohort of 235 patients, >90% of patients were treated with Palbociclib in combination with either an aromatase inhibitor (AI) or fulvestrant (FUL). Tumor evolution occurs on treatment with CDK4/6i; however, analyses of pretreatment biopsies can inform the duration of PFS. These data support discrete biological processes associated with sensitivity/resistance. Predictive algorithms could be developed to inform features of treatment decision which will require prospective validation which is ongoing.
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HTG EdgeSeq Oncology Biomarker Panel (OBP) • Breast Cancer Index®
|
Ibrance (palbociclib) • fulvestrant
over1year
Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study. (PubMed, Breast Cancer Res)
These findings are consistent with the growing body of evidence that BCI (H/I) is significantly predictive of response to EET and outcome. Results from this direct comparison demonstrate that expression of ER, PR, AR, Ki67 or AR/ER ratio are not predictive of benefit from EET. BCI (H/I) is the only clinically validated biomarker that predicts EET benefit.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • AR (Androgen receptor) • HOXB13 (Homeobox B13) • IL17RB (Interleukin 17 Receptor B)
|
PGR expression
|
Breast Cancer Index®
|
tamoxifen
over1year
New data presented at SABCS 2022 reveal expanded predictive value of the Breast Cancer Index™ test for ovarian function suppression in premenopausal women with HR+ breast cancer (Hologic Press Release)
"Hologic, Inc...and its subsidiary, Biotheranostics, Inc...announced new study data showing that the Breast Cancer Index test identified which premenopausal patients with early-stage, hormone-receptor positive (HR+) breast cancer benefited from the addition of ovarian function suppression (OFS) to primary adjuvant endocrine therapy...The translational study results are featured in the official press program at the 2022 San Antonio Breast Cancer Symposium (SABCS) being held from December 6-10, 2022."
Retrospective data
|
Breast Cancer Index®
over1year
Genomic assays for lobular breast carcinoma. (PubMed, J Clin Transl Res)
Prospective studies on ILC with genomic assays are warranted given the various subtypes of and treatment options for this underestimated, but frequently occurring cancer. Genomic assays can be employed in ILC patients to predict the risk of recurrence and identify those patients who might benefit from chemotherapy in addition to their standard treatment regimen.
Review • Journal
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint • Breast Cancer Index® • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
over1year
Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays? (PubMed, Cancer Treat Rev)
Several prospective and retrospective studies have investigated the correlation between gene expression risk score from core needle biopsy before neoadjuvant therapy and the likelihood of 1) clinical and pathological response to neoadjuvant chemotherapy and endocrine therapy, 2) conservative surgery after neoadjuvant chemotherapy and endocrine therapy, and 3) survival following neoadjuvant chemotherapy and endocrine therapy. The purpose of this review is to provide an overview of the potential clinical utility of the main commercially available gene expression panels (Oncotype DX, MammaPrint, EndoPredict, Prosigna/PAM50 and Breast Cancer Index) in the neoadjuvant setting, in order to better inform decision making for luminal BC beyond the exclusive contribution of clinico-pathological features.
Retrospective data • Review • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • EGFR positive • HR positive + HER-2 negative
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint • Breast Cancer Index® • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
over1year
Estrogen receptor reprogramming by HOXB13 and GATA3 in ER-positive breast cancer cells (SABCS 2022)
This study lends further support to a model of HOXB13-mediated reprogramming of the ER cistrome in breast cancer. Motif analysis of HOXB13-induced chromatin opening suggests interactions with other pioneer transcription factors including FOXA1 and GRHL1, while HOXB13-induced transcriptional activation is associated with motifs for activating factors such as AP-1. These results will be expanded to inducible cell lines to further characterize the effects of HOXB13 expression on ER binding and function.
ER (Estrogen receptor) • AR (Androgen receptor) • FOXA1 (Forkhead Box A1) • GATA3 (GATA binding protein 3) • HOXB13 (Homeobox B13) • IL17RB (Interleukin 17 Receptor B)
|
ER positive • HOXB13 expression
|
Breast Cancer Index®
over1year
Biomarker associated with response to CDK4/6 inhibitors in metastatic hormone receptor positive breast cancer (SABCS 2022)
Patients and In this cohort of 235 patients, >90% of patients were treated with Palbociclib in combination with either an aromatase inhibitor (AI) or fulvestrant (FUL). Tumor evolution occurs on treatment with CDK4/6 inhibitors; however, analyses of pretreatment biopsies can inform the duration of PFS. These data support discrete biological processes associated with sensitivity/resistance. Predictive algorithms could be developed to inform features of treatment decision which will require prospective validation which is ongoing.
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HR positive
|
HTG EdgeSeq Oncology Biomarker Panel (OBP) • Breast Cancer Index®
|
Ibrance (palbociclib) • fulvestrant
over1year
HOXB13/IL17RB-low breast cancers are predicted to respond to PIK3CA inhibitors independent of PIK3CA mutational status (SABCS 2022)
No-significant associations between the PPI dysreg magnitude of the drug-associated leading-edge genes and PIK3CA mutational status was observed (AZD6482 FDR=0.736 and A66 FDR=0.95). No significant genetic alteration, including PIK3CA mutational status, was identified between H/I-high and H/I-low groups. Thus, protein- protein interaction (PPI) dysregulation analysis identifies H/I-low BC tumors as those that are predicted to response to PIK3CA inhibitors independent of PIK3CA mutational status.
BRCA Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA2 (Breast cancer 2, early onset) • CCND1 (Cyclin D1) • FGF19 (Fibroblast growth factor 19) • CDH1 (Cadherin 1) • HOXB13 (Homeobox B13) • IL17RB (Interleukin 17 Receptor B)
|
HR positive • PIK3CA mutation
|
Breast Cancer Index®
|
AZD6482
over1year
Validation of the Breast Cancer Index (BCI) prognostic models optimized for late distant recurrence in postmenopausal women with early-stage HR+ breast cancer in the TEAM trial (SABCS 2022)
We have previously shown that the Breast Cancer Index (BCI) and BCIN+ prognostic models were significantly prognostic for risk of overall (0-10y) and late (5-10y) distant recurrence (DR) in N0 and N1 HR+ patients in the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial... Compared to the original BCI/BCIN+ models, the optimized BCI and BCIN+ models showed improved prognostic performance for identifying low-risk patients with a very low risk of late DR (< 4%), for both N0 and N1 patients . These results provide further validation of BCI clinical utility as an aid in the decision-making for extended endocrine therapies for HR+ breast cancer, particularly in patients with N1 disease that may be spared extended endocrine treatment.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
Breast Cancer Index®
|
tamoxifen
over1year
Correlating predicted adjuvant therapy benefit and risk of recurrence between Breast Cancer Index (BCI) and 21-gene oncotype DX Recurrence Score (RS) (SABCS 2022)
In our patient population selected to have Oncotype DX and BCI performed, we found no association between the two genomic assays in terms of their predictive benefit. However, there was an association between Oncotype DX and BCI in terms of their prognostic ability. Given the increased use of BCI since its inclusion in national guidelines, it is important to understand its relationship with other genomic assays especially when used to guide clinical decisions and estimate prognosis.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HR positive • HER-2 negative
|
Breast Cancer Index® • Oncotype DX Breast Recurrence Score®Test
over1year
Clinical use of Breast Cancer Index for prediction of late breast cancer recurrence and prediction of benefit in extended endocrine therapy: A single institution experience (SABCS 2022)
This single-institution study revealed that clinicians make decisions regarding extended endocrine therapy that are usually concordant with BCI predictive results. CTS5 results weakly correlate with BCI prognostic results but may not provide conclusive information to support a clinical decision. For patients with early hormone-receptor positive breast cancer the BCI tissue-based analysis may influence a decision regarding extending endocrine therapy.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • HOXB13 (Homeobox B13) • IL17RB (Interleukin 17 Receptor B)
|
HR positive
|
Breast Cancer Index® • Oncotype DX Breast Recurrence Score®Test
over1year
Prospective assessment of the decision-making impact of the Breast Cancer Index in the BCI Registry Study (SABCS 2022)
This first analysis in a large patient cohort of the BCI Registry confirms previous findings on the significant clinical decision-making impact of BCI for extending adjuvant endocrine therapy. Incorporating BCI into clinical practice resulted in changes in physician recommendations for EET in over 40% of cases, while at the same time increasing physician confidence in their recommendations. Knowledge of the BCI result also improved patient satisfaction and reduced patient concerns regarding cost, drug safety and benefit of EET.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
Breast Cancer Index®
over1year
Evaluation of the Breast Cancer Index in premenopausal women with early-stage HR+ breast cancer in the SOFT trial (SABCS 2022)
Background: The landmark Suppression of Ovarian Function Trial (SOFT) in premenopausal breast cancer patients revealed that the addition of ovarian function suppression (OFS) to adjuvant endocrine therapy with either tamoxifen (T+OFS) or exemestane (E+OFS) reduces the risk of recurrence compared with adjuvant tamoxifen alone... Tumor samples from 1687 (98%) patients (30.4% < 40 years, 64.1% T1, 50.1% G2, 65.8% N0, 85.5%% HER2-, 53.3% received prior chemotherapy) were successful in BCI testing and included in the final analysis. Patient characteristics in the translational cohort are representative of the parent SOFT trial. 42.4% of patients’ tumors had H/I-High status.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
Breast Cancer Index®
|
tamoxifen
over1year
Breast Cancer Index (BCI) identifies fewer patients with high risk of late recurrence and high likelihood of benefit from extended endocrine therapy with invasive lobular compared to invasive ductal carcinoma (SABCS 2022)
BCI identified a smaller proportion of patients with ILC at High Risk of late DR and High Likelihood of benefit from EET compared to IDC. Data from the IDEAL translational study showed that while fewer patients with ILC were identified as BCI (H/I)-High, they still derived similar absolute benefit compared to the overall cohort, while those classified as BCI (H/I)-Low derived no benefit from EET.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • HOXB13 (Homeobox B13) • IL17RB (Interleukin 17 Receptor B)
|
Breast Cancer Index®
over1year
The Utility of Breast Cancer Index (BCI) Over Clinical Prognostic Tools for Predicting the Need for Extended Endocrine Therapy: A Safety Net Hospital Experience. (PubMed, Clin Breast Cancer)
BCI is reasonable to consider in early-stage HR+ BC and offered clinically relevant information over clinical pathologic information alone.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HR positive • HER-2 negative
|
Breast Cancer Index®
over1year
Validation of a New Prognostic Breast Cancer Index Based on Classical Clinicopathologic Information (CAP 2022)
In this study we could validate the prognostic power of the API in a large independent cohort of breast cancer patients. This corroborates the significance of classical clinicopathologic parameters and especially underlines the importance of the histopathologic tumor type.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive
|
Breast Cancer Index®
over1year
Validation of a New Prognostic Breast Cancer Index Based on Classical Clinicopathologic Information (CAP 2022)
In this study we could validate the prognostic power of the API in a large independent cohort of breast cancer patients. This corroborates the significance of classical clinicopathologic parameters and especially underlines the importance of the histopathologic tumor type.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive
|
Breast Cancer Index®
over1year
Implications for clinical care (SABCS 2022)
Current data on the role of circulating biomarkers including ctDNA, to identify at risk patients will be discussed as will open questions on how this might impact treatment approach. Finally, possible therapeutic approaches following the identification minimal residual or dormant disease will be reviewed, as will trial design options in this rapidly evolving space in breast oncology.
Clinical
|
Breast Cancer Index®
over1year
Clinical Utility of Genomic Assay in Node-Positive Early-Stage Breast Cancer. (PubMed, Curr Oncol)
This paper will review the Oncotype DX 21-gene Recurrence Score (RS), MammaPrint, EndoPredict, Prosigna, and Breast Cancer Index (BCI) genomic assays. We will also focus on these genomic assays' clinical application and utility in node-positive early-stage BC based on the most recent evidence and guidance recommendations.
Journal • Review
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 negative
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint • Breast Cancer Index® • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
over1year
Prognostic performance of Breast Cancer Index (BCI) in postmenopausal women with early-stage HR+ breast cancer in the TEAM trial (ESMO 2022)
Here, the prognostic performance of BCI and BCIN+ was evaluated in a cohort of HR+ postmenopausal women from the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial...Table: 138MO conclusions BCI and BCIN+ are significantly prognostic for risk of overall DR (0-10y) and late DR (5-10y) for N0 and N1 patients, respectively. These results provide further validation of BCI clinical utility as an aid in the decision-making for adjuvant therapies for HR+ breast cancer.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
Breast Cancer Index®
|
tamoxifen
over1year
A New Nonparametric Multivariate Control Scheme for Simultaneous Monitoring Changes in Location and Scale. (PubMed, Comput Math Methods Med)
Simulation results show that the proposed scheme can efficiently detect a range of shifts. The proposed chart can trigger an alert and timely discover the change of the breast cancer index.
Journal
|
Breast Cancer Index®